Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for aggressive lung cancer

NCT ID NCT04702880

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding an experimental drug (BMS-986012) to standard chemotherapy and immunotherapy could help people with advanced small cell lung cancer live longer without their cancer growing. The trial involved 135 newly diagnosed patients. Researchers measured safety and how well the treatment worked compared to standard care alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

135 people

The number who actually took part.

Started

Mar 2021

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically documented extensive-stage small cell lung cancer (ES-SCLC) and extensive-stage disease (American Joint Committee on Cancer, 8th edition, Stage IV \[T any, N any, M1a, M1b, or M1c\], or T3-4 due to multiple lung nodules that are too extensive or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan) * Participants taking part in the separate PET tracer sub-study must provide a fresh tumor biopsy from any disease site (primary or metastatic) * Archived tumor specimens, in the form of blocks or sectioned slides, are mandatory for all participants except those participating in the separate PET tracer sub-study for whom the archived tumor specimen is optional * Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 * At least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria * Adequate hematologic and end organ function * Must agree to follow specific methods of contraception, if applicable Exclusion Criteria: * Women who are pregnant or breastfeeding. Japan only: participation in the study is not allowed even if breastfeeding is suspended * Prior chemotherapy, radiation therapy, or biologic therapy for SCLC. Previously treated limited stage SCLC (LS-SCLC) participants are also excluded * Symptomatic brain or other central nervous system (CNS) metastases * Paraneoplastic autoimmune syndrome requiring systemic treatment * History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan * Grade ≥ 2 peripheral sensory neuropathy at study entry * Significant uncontrolled cardiovascular disease * Active, known or suspected autoimmune disease or inflammatory disorder Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extensive-stage small-cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extensive-stage small-cell lung cancer

Contacts and locations

Locations

  • Local Institution

    Cincinnati, Ohio, 45267, United States

  • Local Institution

    Dallas, Texas, 75390, United States

  • Local Institution - 0001

    Malvern, Victoria, 3144, Australia

  • Local Institution - 0002

    Durham, North Carolina, 27710, United States

  • Local Institution - 0003

    Westmead, New South Wales, 2145, Australia

  • Local Institution - 0004

    Murdoch, Western Australia, 6150, Australia

  • Local Institution - 0005

    Majadahonda, 28222, Spain

  • Local Institution - 0006

    Málaga, 29010, Spain

  • Local Institution - 0007

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Local Institution - 0012

    Edmonton, Alberta, T6G 1Z2, Canada

  • Local Institution - 0021

    Madrid, 28041, Spain

  • Local Institution - 0022

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 0023

    Greenslopes, Queensland, 4120, Australia

  • Local Institution - 0029

    Rozzano, 20089, Italy

  • Local Institution - 0030

    Peschiera del Garda, 37019, Italy

  • Local Institution - 0031

    Pisa, 56124, Italy

  • Local Institution - 0034

    Ghent, 9000, Belgium

  • Local Institution - 0036

    Athens, 11527, Greece

  • Local Institution - 0038

    Athens, 185 47, Greece

  • Local Institution - 0039

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Local Institution - 0040

    Groningen, 9700RB, Netherlands

  • Local Institution - 0041

    Craiova, 200542, Romania

  • Local Institution - 0042

    Cluj-Napoca, 400015, Romania

  • Local Institution - 0043

    Bucharest, 022328, Romania

  • Local Institution - 0045

    Heraklion, Irakleío, 715 00, Greece

  • Local Institution - 0048

    Lodz, 93-338, Poland

  • Local Institution - 0049

    Gdansk, 80-214, Poland

  • Local Institution - 0050

    Liège, 4000, Belgium

  • Local Institution - 0051

    Charleroi, Hainaut, 6060, Belgium

  • Local Institution - 0060

    Cincinnati, Ohio, 45267, United States

  • Local Institution - 0064

    Brampton, Ontario, L6R 3J7, Canada

  • Local Institution - 0066

    Arnhem, 6815 AD, Netherlands

  • Local Institution - 0067

    Cleveland, Ohio, 44106-1716, United States

  • Local Institution - 0069

    Takatsuki, Osaka, 5698686, Japan

  • Local Institution - 0070

    Ōsaka-sayama, Osaka, 589-8511, Japan

  • Local Institution - 0073

    Sendai, Miyagi, 980-0873, Japan

  • Local Institution - 0075

    Birmingham, Alabama, 35249, United States

  • Local Institution - 0077

    Ina-machi, Saitama, 362-0806, Japan

  • Local Institution - 0081

    Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.